KYMERA THERAPEUTICS INC's ticker is KYMR and the CUSIP is 501575104. A total of 128 filers reported holding KYMERA THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.46 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $66,030,560 | -34.4% | 4,750,400 | +8.6% | 0.38% | -34.5% |
| Q2 2023 | $100,589,067 | +17.9% | 4,375,340 | +51.9% | 0.58% | +25.4% |
| Q1 2023 | $85,329,215 | +18.7% | 2,879,825 | 0.0% | 0.46% | +7.4% |
| Q4 2022 | $71,880,432 | +14.7% | 2,879,825 | 0.0% | 0.43% | +5.1% |
| Q3 2022 | $62,694,000 | +10.6% | 2,879,825 | 0.0% | 0.41% | +27.6% |
| Q2 2022 | $56,704,000 | -43.8% | 2,879,825 | +20.8% | 0.32% | -44.5% |
| Q1 2022 | $100,922,000 | -33.3% | 2,384,742 | 0.0% | 0.58% | -21.3% |
| Q4 2021 | $151,407,000 | +8.1% | 2,384,742 | 0.0% | 0.74% | +19.8% |
| Q3 2021 | $140,080,000 | +47.4% | 2,384,742 | +21.7% | 0.62% | +47.5% |
| Q2 2021 | $95,022,000 | +24.8% | 1,959,211 | 0.0% | 0.42% | +26.4% |
| Q1 2021 | $76,135,000 | -37.3% | 1,959,211 | 0.0% | 0.33% | -27.9% |
| Q4 2020 | $121,471,000 | +91.9% | 1,959,211 | 0.0% | 0.46% | +81.0% |
| Q3 2020 | $63,302,000 | – | 1,959,211 | – | 0.25% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Atlas Venture Life Science Advisors, LLC | 5,858,262 | $81,429,842 | 12.61% |
| Aquilo Capital Management, LLC | 782,219 | $10,872,844 | 9.85% |
| BVF INC/IL | 4,739,004 | $65,872,156 | 1.78% |
| Redmile Group, LLC | 1,868,507 | $25,972,247 | 1.24% |
| Artal Group S.A. | 1,805,346 | $25,094 | 1.08% |
| Deer Management Co. LLC | 615,895 | $8,560,941 | 1.04% |
| Avoro Capital Advisors LLC | 3,855,000 | $53,584,500 | 0.84% |
| Rock Springs Capital Management LP | 1,504,351 | $20,910,479 | 0.56% |
| AtonRa Partners | 19,172 | $266,491 | 0.56% |
| Baker Brothers Advisors | 4,750,400 | $66,030,560 | 0.38% |